Vance M L, Evans W S, Thorner M O
Ann Intern Med. 1984 Jan;100(1):78-91. doi: 10.7326/0003-4819-100-1-78.
Bromocriptine, a specific dopamine receptor agonist, has been used for the treatment of various hyperprolactinemic conditions and as adjunctive therapy for acromegaly (with or without concomitant hyperprolactinemia) and Parkinson's disease. Bromocriptine is extremely effective in suppressing prolactin secretion regardless of the cause, in restoring gonadal function and fertility, and in decreasing the size of prolactin-secreting pituitary tumors. Most patients with acromegaly have clinical improvement with this drug. When bromocriptine is added to a regimen of levodopa or carbidopa, patients with Parkinson's disease frequently have additional clinical improvement and, in most patients, the levodopa or carbidopa dose can be reduced. Withdrawal of bromocriptine therapy is associated in most patients with reversal of its beneficial effects--return of hyperprolactinemia, return of excess growth hormone secretion, and exacerbation of Parkinson's disease.
溴隐亭是一种特异性多巴胺受体激动剂，已被用于治疗各种高催乳素血症，也作为肢端肥大症（伴或不伴高催乳素血症）和帕金森病的辅助治疗药物。无论病因如何，溴隐亭在抑制催乳素分泌、恢复性腺功能和生育能力以及缩小分泌催乳素的垂体瘤大小方面都极为有效。大多数肢端肥大症患者使用该药后临床症状有所改善。当溴隐亭与左旋多巴或卡比多巴联合使用时，帕金森病患者的临床症状常常会进一步改善，并且在大多数患者中，左旋多巴或卡比多巴的剂量可以减少。在大多数患者中，停用溴隐亭治疗会导致其有益效果逆转——高催乳素血症复发、生长激素分泌过多复发以及帕金森病加重。
